A secondary comparison examined the effects of medications approved for AUD, such as disulfiram, acamprosate, and naltrexone
Are there side effects specific to non-diabetic GLP-1 users
Monitoring blood-brain barrier integrity following amyloid- immunotherapy using gadolinium-enhanced MRI in a PDAPP mouse model
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark Phase 3 cardiovascular outcomes trial enrolling 17,604 adults with preexisting cardiovascular disease and obesity or overweight, but WITHOUT diabetes
Only participants with a nonmissing week 36 weight measurement value and at least 1 nonmissing weight measurement value after week 36 were included in the analysis
18, 2024 from Durell, N., Franks, R., Coon, S., et al